NCT04134923

Imaging Biomarkers in Preclinical and Symptomatic AD

Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 375 (estimated)
• Sponsor: Tammie L. S. Benzinger, MD, PhD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

Detailed description

This study will use a radioactive tracer called \[11C\]-Pittsburgh Compound B (11C\]PIB), which is a tracer that binds to beta amyloid protein in the brain. This compound is considered investigational, which means that it has not been approved by the United States Food and Drug Administration (FDA).

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	[11C] Pittsburgh Compound-B (PIB)	Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.

Timeline

• Start date: 2021-06-08
• Primary completion: 2026-10-01
• Completion: 2029-10-01
• First posted: 2019-10-22
• Last updated: 2025-08-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study